A new research highlight has been published in the journal “Signal Transduction and Targeted Therapy”. It discusses a recent case of a potential HIV cure using a combination of haploidentical stem cells and HLA-mismatched cord blood.

1. The Case: The case involves a woman of mixed race who was treated for acute myeloid leukemia (AML), a type of cancer, and was also infected with HIV. This is the fourth case of a potential cure for HIV infection ever, the first in a woman, the first in a person of mixed race, and the first in which a specific type of transplant was used.
2. The Method: The treatment involved a transplant of hematopoietic stem cells, which are cells that can become any type of blood cell. These cells were taken from two sources: a “haploidentical” donor (a family member who is a half-match for certain important immune system genes) and cord blood that was not a perfect match for the patient’s immune system genes (HLA-mismatched). The cord blood cells had a specific mutation (CCR5Δ32/Δ32) that makes them resistant to HIV.
3. The Outcome: After the transplant, the woman’s HIV levels became undetectable, and they remained so even after she stopped taking antiretroviral therapy (ART), the standard treatment for HIV. This suggests that she may be cured of HIV.
4. The Significance: This case is significant for several reasons. First, it shows that this type of transplant can potentially cure HIV, even in people of diverse ancestry who may have a harder time finding a matching donor. Second, the patient did not develop graft-versus-host disease (GvHD), a common and serious complication of transplants, suggesting that this method may be safer than others. Finally, the case provides hope for future developments in gene and cell therapy for HIV.
5. The Challenges: Despite the success of this case, there are still many challenges to curing HIV. For example, the virus can hide in “reservoirs” in the body, making it difficult to completely eliminate. Also, while the patient in this case was cured, another patient who received a similar treatment was not, showing that the method is not foolproof. Finally, while modern immunotherapy approaches may offer a less risky path to an HIV cure, they also have potential side effects and risks.

In summary, this case represents a significant step forward in the search for a cure for HIV. However, more research is needed to confirm these results and to further improve the safety and effectiveness of these treatments.